An Early Phase 1 interventional study of Cholate testing in Liver Disease and Cardiovascular Disease, sponsored by Northwestern University. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-08-22.
Sponsored by Northwestern University · Early Phase 1, Interventional, and Diagnostic
Background: It is still difficult to predict the outcome in patients requiring Fontan Revisions and in those who have evidence of congestive hepatopathy and probable cirrhosis requiring major cardiac surgery including heart transplant. Over the years, many prognostic indices have been derived from laboratory results of blood tests, clinical and physiological variables (or some combination thereof), from liver imaging to liver histology, which has issues of sampling error, medical risks and technical difficulty. None of these have proved entirely satisfactory. Predicting morbidity or survival is particularly important when deciding about Fontan revisions versus the need for heart transplantation. What is needed here is a truly reliable test of liver function that can help predict outcome, on the basis of a single measurement within few days of a planned revision. For this purpose, it is desirable that the chosen tests of liver performance be safe, non-invasive, easy to perform, have a rapid turnaround for results, and be readily repeatable.
Tests of hepatic elimination of various exogenous substances have been described, such as galactose elimination capacity (GEC), indocyanine green (ICG) clearance, lidocaine metabolism to monoethylglycinexylidide (MEGX), and other tests that rely on liver metabolic capacity. None of these metabolic or clearance tests achieved widespread acceptance or use, mostly because their performance and analyses were cumbersome.
HepQuant,LLC has developed a platform of tests of liver function which include Systemic Hepatic Filtration Rate (HFR), Portal HFR, SHUNT, and Disease Severity Index (DSI)1,2. HepQuant tests specifically target the hepatic uptake of cholate and use a single noninvasive test of 90 minutes duration to quantify the systemic circulation, portal circulation, and portal-systemic shunt and to derive a DSI in intact human subjects. HepQuant tests can assess all stages and etiologies of liver disease. In chronic HCV patients HepQuant testing can predict which patients will respond to antiviral therapy and can measure the improvement in hepatic function that occurs after successful antiviral therapy. Patients who did not respond were followed for an average of 5 years and up to 8 years, and baseline HepQuant testing could predict clinical outcomes (CTP progression, variceal bleeding, encephalopathy, ascites, liver-related death) with 87% sensitivity and 71% specificity.
Hypothesis The results of HepQuant in patients with CHD will correlate with outcomes of cardiac surgery (namely morbidity as defined by complications such as ischemic hepatitis, survival, need for heart transplantation, improvement of liver function post revision), and thus can be used for prognosis in this condition, either alone or in conjunction with other clinical, physiological, and laboratory prognostic scores, thereby giving clinical guidance concerning the need for heart transplantation and simultaneous liver transplantation..
Primary Aim To assess the relationship between HepQuant testing results and clinical outcomes in patients with liver disease secondary to congenital heart disease (CHD) undergoing Fontan revisions.
To assess the clinical outcomes of patients with liver disease secondary to acquired cardiomyopathy or valvular disease that will undergo extensive heart surgery or heart transplantation.
Secondary Aim To assess whether HepQuant testing predicts clinical outcome in patients with Liver Disease and CHD when used in conjunction with other diagnostic tests, such as MELD, Child-Turcotte-Pugh (CTP), liver stiffness measurement (US with ARFI), and Fibrotest (Fibrosure).
Study population Male and female Subjects (age 18 to 70 years) with liver disease secondary to congenital heart disease or cardiomyopathy.
2,081 studies on the registry are indexed under Liver Diseases; 390 are open to participants now.
This study's enrollment of 14 is below the median of 50 across 1,323 interventional studies indexed under Liver Diseases.
Browse Liver Diseases studies →Northwestern University is the lead sponsor of 1,396 studies on the registry; 199 are open to participants now.
Of its 102 completed or terminated interventional studies of FDA-regulated products, 73 (72%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
diagnostic measure of liver function
Drug: Cholate testing
The patient receives simultaneously an oral dose of d4-cholate and an IV dose of 13C-cholate, which are stable isotopes; there is no radioactivity or radiation exposure.
Also known as: 13C-cholate, d4-cholate
Liver Function
Liver function as measured by HepQuant testing which include Systemic Hepatic Filtration Rate (HFR), Portal HFR, SHUNT.
Time frame: 6 months
No study locations are listed for this record.
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Northwestern University